EZH2 Inhibitor Tazemetostat in Pediatric Subjects With Relapsed or Refractory INI1-Negative Tumors or Synovial Sarcoma

NCT02601937 · clinicaltrials.gov ↗

PHASE1

Phase

COMPLETED

Status

109

Enrollment

INDUSTRY

Sponsor class

Conditions

Rhabdoid Tumors
INI1-negative Tumors
Synovial Sarcoma
Malignant Rhabdoid Tumor of Ovary

Interventions

DRUG: Tazemetostat

Sponsor

Epizyme, Inc.